Liver Receptor Homolog-1 (LRH-1; NR5A2)
Assay available as Screening Service
This nuclear receptor assay system utilizes proprietary non-human mammalian cells engineered to provide high-level expression of a hybrid form of the Human Liver Receptor Homolog-1 (NR5A2), commonly called LRH-1. The N-terminal DNA binding domains (DBD) of the native LRH-1 has been substituted with that of the yeast GAL4-DBD. The reporter gene is beetle luciferase functionally linked to the GAL4 upstream activation sequence (UAS).
As is true in vivo, these reporter cells express LRH-1 that is constitutively active in the (putative) absence of ligand binding. A ligand binding event may diminish the constitutive activity of the receptor (an inverse-agonist response), or further elevates the already high constitutive activity of LRH-1 (an agonist response).
LRH-1 is a nuclear receptor that is an essential regulator of gene transcription, critical for early cellular development and imperative for the proper functions of the liver, pancreas, and intestines during the adult life. In the liver, LRH-1 regulates the expression of key genes involved in bile acid synthesis, cholesterol homeostasis and transport. Because of its decisive role in cell differentiation, LRH-1 is linked to multiple developmental pathways. LRH-1 activity is linked to breast and endometrial cancers as well as intestinal tumors and cancer of the pancreas.
For more information on LRH-1, visit the Nuclear Receptor Resource.
Service Assays: Human
The primary application of INDIGO’s cell-based nuclear receptor assays are to quantitatively assess the bioactivity of a test compound as an agonist (activator) or antagonist (inhibition of an agonist response) of a given receptor. Service assays include a positive control reference compound and ‘vehicle’ control for every experiment. A formal study report and all data files are provided to the client upon completion of the study. To receive a quote for your proposed study, complete & submit the online “Request a Quote” form or contact an INDIGO Customer Service Representative to discuss your desired study parameters.
In vitro toxicology platform provides predictive model of liver toxicity. Aims to reduce the high rates of drug-induced liver damage State College, PA (May 4, 2016) INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has completed development of an in vitro toxicology platform, meeting the demand for predictive liver toxicity models. INDIGO’s in
New Assay Critical to the Study of Diabetes, Pancreatic Cancer, and Metabolic Diseases State College, PA (January 20, 2016) INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded its offerings to include liver homology receptor-1 (LRH-1) kits and services. LRH-1, also called NR5A2, is a nuclear receptor that is an essential regulator